Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01016262|
Recruitment Status : Terminated (The decision was taken solely for business/administrative reasons, no safety considerations entered into this. Ongoing randomized patients to complete.)
First Posted : November 19, 2009
Last Update Posted : July 7, 2011
Hypothesis: The responder rate of the MAX-002 will be superior to placebo after 6 weeks of treatment in patients with mild to moderate ulcerative proctitis.
Summary: The primary purpose of this study is to evaluate the efficacy and safety of new mesalamine suppositories (MAX-002) as compared to placebo after 6 weeks of treatment in adults with mild to moderate ulcerative proctitis.
Prior to randomization, all inclusion and exclusion criteria will be verified to confirm eligibility. Patients found to be eligible will be randomized in a 1:1:1 scheme to receive either MAX-002 1 g, Canasa® 1 g, or Placebo suppository once daily at bedtime for 6 weeks in a double-blind fashion. Completers at Study Week 6 will be offered to receive MAX-002 1 g suppositories on a voluntary basis during the next 8 weeks of the open-label phase. Regardless of the treatment groups, all patients will be evaluated through phone calls at Study Weeks 1 and 2 followed by clinical visits at Study Weeks 3, 6, and 14. Study-specific procedures include but are not limited to the following: flexible proctosigmoidoscopy; disease activity assessment; smoking habits description; health-related quality of life; compliance to treatment check and safety evaluations (physical examinations, ECG, vitals signs, clinical laboratory analyses). All patients will complete daily diaries and will be asked general open questions about any occurrence of adverse events/concurrent medical conditions, use of adjunctive therapy/procedure, and their intake of concomitant medication.
|Condition or disease||Intervention/treatment||Phase|
|Ulcerative Proctitis||Drug: MAX-002 Drug: Placebo Drug: Canasa®||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||549 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis|
|Study Start Date :||September 2009|
|Estimated Primary Completion Date :||July 2011|
|Estimated Study Completion Date :||September 2011|
|Experimental: MAX-002 suppositories||
MAX-002 1 g suppositories will be taken once daily at bedtime for 6 weeks during the double-blind phase. Completers at Study Week 6 will be offered to receive, on a voluntary basis, MAX-002 1 g suppositories once daily at bedtime for 8 weeks during the open-label phase.
|Placebo Comparator: Placebo suppositories||
Placebo suppositories will be taken once daily at bedtime for 6 weeks during the double-blind phase.
|Active Comparator: Canasa® suppositories||
Canasa® 1 g suppositories will be taken once daily at bedtime for 6 weeks during the double-blind phase.
- The responder rate at Week 6 [ Time Frame: 6 weeks ]
- The responder rate at Week 3 [ Time Frame: 3 weeks ]
- Rectal bleeding at Week 6 [ Time Frame: 6 weeks ]
- Total Inflammatory Bowel Disease Questionnaire (IBDQ) score at Week 6 (health economics evaluation) [ Time Frame: 6 weeks ]
- Time to relief of tenesmus [ Time Frame: 6 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01016262
Show 40 Study Locations
|Study Director:||Marielle Cohard-Radice, M.D.||Axcan Pharma|